What is the recommended management for an acute exacerbation of interstitial lung disease?

Management of Acute Exacerbation of Interstitial Lung Disease

For acute exacerbation of ILD, immediately initiate pulse intravenous methylprednisolone as first-line therapy, combined with rituximab, cyclophosphamide, or mycophenolate depending on the underlying disease subtype. 1

Initial Assessment and Diagnosis

Before diagnosing acute exacerbation (AE-ILD), you must systematically exclude alternative causes of acute respiratory deterioration:

• Rule out infection (bacterial pneumonia, viral pneumonia, opportunistic infections)
• Rule out heart failure (pulmonary edema)
• Rule out pulmonary embolism
• Rule out pneumothorax

The diagnosis requires: acute worsening of dyspnea (typically <1 month), new bilateral ground-glass opacities or consolidation on imaging, and absence of alternative explanations 2, 3.

First-Line Pharmacologic Management

Corticosteroids (Foundation of Treatment)

Pulse intravenous methylprednisolone is conditionally recommended as first-line therapy for rapidly progressive ILD (RP-ILD). 1 This provides rapid onset of action in life-threatening situations. Follow with high-dose oral prednisone after the pulse therapy.

Critical exception: In systemic sclerosis (SSc)-ILD, there is a strong recommendation AGAINST glucocorticoids due to risk of scleroderma renal crisis, particularly at doses >15 mg/day prednisone equivalent 1. However, in the rare case of RP-ILD in SSc, an individualized approach may be warranted given the life-threatening nature.

Immunosuppressive Agents (Use in Combination)

For RP-ILD, use upfront combination therapy rather than monotherapy 1:

• Triple therapy (glucocorticoids + 2 immunosuppressants) for confirmed or suspected MDA-5 positive disease
• Double or triple therapy for non-MDA-5 disease

First-line immunosuppressive options (conditionally recommended) 1:

• Rituximab - particularly strong evidence from RECITAL trial showing similar efficacy to cyclophosphamide with different toxicity profile
• Cyclophosphamide - traditional agent with established efficacy
• Mycophenolate - preferred for chronic ILD, can be used in acute settings
• IVIG - especially useful when rapid onset needed or in IIM-ILD/MCTD-ILD
• Calcineurin inhibitors (CNIs) - tacrolimus or cyclosporine
• JAK inhibitors - emerging option

Disease-Specific Considerations

Idiopathic Inflammatory Myopathy (IIM)-ILD

• CNIs are beneficial, particularly in anti-synthetase syndrome or MDA-5 positive disease 1
• JAK inhibitors are emerging treatment options 1
• IVIG is particularly useful with severe respiratory muscle weakness 1

Systemic Sclerosis (SSc)-ILD

• Strongly avoid glucocorticoids 1
• Consider tocilizumab in early progressive disease with diffuse skin involvement and elevated acute phase reactants 1

Rheumatoid Arthritis (RA)-ILD

• Tocilizumab conditionally recommended despite limited evidence, given favorable safety profile 1

Respiratory Support Strategy

Oxygen Therapy Hierarchy

1. High-flow nasal cannula (HFNO) - initiate early to minimize progression to invasive mechanical ventilation 3, 4
2. Non-invasive ventilation (NIV) - for worsening hypoxemia and/or hypercapnia 4
3. Invasive mechanical ventilation - only when absolutely necessary, as mortality remains extremely high

Mechanical Ventilation Parameters (If Required)

• Low tidal volumes (lung-protective strategy) to minimize ventilator-induced lung injury 4
• Avoid high PEEP - may be less effective and associated with increased mortality 4
• Prone positioning - can improve oxygenation in severe hypoxemia 4
• Lowest FiO2 that maintains safe oxygen saturation 5

Advanced Therapies

ECMO

Reserved for the most severe cases as a bridge to transplant or recovery; carries very high risk 4, 6

Lung Transplantation

Early referral is critical - refer before the patient deteriorates to the point of ineligibility 1. For RP-ILD specifically, there is a conditional recommendation for early referral over later referral after progression 1.

Agents to AVOID in Acute Exacerbation

Conditionally recommended AGAINST for first-line RP-ILD treatment 1:

• Methotrexate
• Leflunomide
• Azathioprine
• TNF inhibitors
• Abatacept
• Nintedanib
• Pirfenidone
• Plasma exchange

Supportive Care Essentials

• Careful fluid management - avoid volume overload 4
• Address pulmonary hypertension if present 4
• Broad-spectrum antibiotics - until infection definitively ruled out 6
• Early mobilization when stable 5
• Multimodal analgesia to facilitate breathing 5

Prognosis

Mortality remains extremely high despite treatment, particularly in patients requiring invasive mechanical ventilation 3, 4, 6, 7. This underscores the critical importance of early recognition, aggressive treatment, and prompt transplant evaluation in appropriate candidates.